Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Kos Pharmaceuticals, Inc.
Positive results announced from inhaled insulin therapy phase IIa trial
September 24th, 2004
Kos Pharmaceuticals, Inc., (KOSP) announced positive results from a recently completed 4-week, phase IIa human clinical trial evaluating Kos' inhaled insulin therapy for type 2 diabetic patients. Kos also announced that its KS 01-019 product under development is a combination of Niaspan and simvastatin, the second most widely prescribed statin worldwide for the treatment of dyslipidemia. The New Drug Application (NDA) is projected to be submitted to the U.S. Food and Drug Administration (FDA) in 2006. The results of the phase IIa trial show that Kos' internally developed inhaled insulin formulation is comparable to the market leading injectable...
Source: Food & Drug Law Weekly (2004-09-24)
|
